<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03400072</url>
  </required_header>
  <id_info>
    <org_study_id>P/2017/317</org_study_id>
    <nct_id>NCT03400072</nct_id>
  </id_info>
  <brief_title>Adapted Physical Activity in Patients With Resected Pancreatic Cancer (APACaPOp PRODIGE-56 Study): a National Multicenter Randomized Controlled Phase II Trial</brief_title>
  <acronym>APACaPOp</acronym>
  <official_title>Adapted Physical Activity in Patients With Resected Pancreatic Cancer (APACaPOp PRODIGE-56 Study): a National Multicenter Randomized Controlled Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GERCOR - Multidisciplinary Oncology Cooperative Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Besancon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Exercise during chemotherapy (CT) is a promising strategy to reduce fatigue and improve
      health-related quality of life (HRQoL). Exercise may also have beneficial effects on tumor
      outcome by decreasing insulin resistance, inflammation, and by modulating various pro-tumoral
      signalling pathways. It has been shown to reduce mortality in breast and colorectal cancer
      adjuvant setting.

      This study aims to explore the effects of adapted physical activity (APA) in patients with
      resected pancreatic ductal adenocarcinoma (PDAC).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2018</start_date>
  <completion_date type="Anticipated">May 2024</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>M6 Health-Related quality of life (HRQoL)</measure>
    <time_frame>month 6</time_frame>
    <description>HRQoL will be assessed by the European Organization for Research and Treatment of Cancer quality of life questionnaire (QLQ) C30 at M6, with the following targeted dimensions: global QoL, fatigue, physical functioning, and pain.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">252</enrollment>
  <condition>Pancreas Cancer</condition>
  <condition>Quality of Life</condition>
  <arm_group>
    <arm_group_label>Unsupervised APA program</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>usual care plus a 6-month unsupervised APA program</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Supervised APA program</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>usual care plus a 6-month supervised APA program</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Usual care</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Unsupervised APA program</intervention_name>
    <description>Exercise training program will consist of one supervised demonstration session with the APA professional, thereafter the training will be continued as unsupervised, home-based exercise training sessions.</description>
    <arm_group_label>Unsupervised APA program</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Supervised APA program</intervention_name>
    <description>Exercise training program will consist of one supervised demonstration session with the APA professional, thereafter the training will be continued as unsupervised, home-based exercise training sessions; in addition, patients will attend weekly supervised, hospital-based exercise sessions in groups of patients.</description>
    <arm_group_label>Supervised APA program</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven PDAC

          -  Complete macroscopic resection (R0 or R1 resection)

          -  Patients randomized within 12 weeks of surgery

          -  No evidence of malignant ascites, liver metastasis, spread to other distant abdominal
             organs, peritoneal metastasis, spread to extra-abdominal organs

          -  Sufficient recovery from the operation and fit to take part in the trial

          -  Able to attend for administration of the adjuvant CT

          -  ECOG PS 0-2

          -  Age ≥ 18 years

          -  Life expectancy &gt; 3 months

          -  Dated and signed informed consent

          -  Registration in a national health care system (CMU included).

        Exclusion Criteria:

          -  Macroscopically remaining tumor (R2 resection or TNM stage IV disease)

          -  Histology other than PDAC

          -  Cardiovascular, respiratory, psychiatric, musculoskeletal, or neurological condition
             contra-indicating exercise practice

          -  Pregnancy or breastfeeding

          -  Protected adults (individuals under guardianship by court order). Note: participation
             to another concomitant clinical trial is allowed but the patient must inform and get
             an authorization from the Investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cindy Neuzillet, MD PhDoc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Henri Mondor</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pascal Hammel, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Beaujon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nelly Roldan</last_name>
    <phone>00336 34 46 62 51</phone>
    <email>nelly.roldan@gercor.com.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christine Delpeut</last_name>
    <email>christine.delpeut@gercor.com.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de Besançon</name>
      <address>
        <city>Besançon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christophe Borg, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Christophe Borg, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Brest</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Philippe Metges, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Philippe Metges, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yves Eusen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre-Guillaume Poureau, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Beaujon</name>
      <address>
        <city>Clichy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pascal Hammel, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Pascal Hammel, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cindy Neuzillet, MD</last_name>
    </contact>
    <investigator>
      <last_name>Christophe Tournigand, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cindy Neuzillet, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thomas Walter, MD</last_name>
    </contact>
    <investigator>
      <last_name>Thomas Walter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital privé Jean Mermoz</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jérôme Desrame, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jérôme Desrame, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sébastien Gaujoux, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Sébastien Gaujoux, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patricia Thoreux, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Mutualiste Montsouris</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christophe Louvet, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Christophe Louvet, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Haut-Lévêque</name>
      <address>
        <city>Pessac</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric Terrebonne, MD</last_name>
    </contact>
    <investigator>
      <last_name>Eric Terrebonne, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Reims</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier Bouché, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Olivier Bouché, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Rouen</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lilian Schwarz, MD</last_name>
    </contact>
    <investigator>
      <last_name>Lilian Schwarz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rosine Guimbaud, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Rosine Guimbaud, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2018</study_first_submitted>
  <study_first_submitted_qc>January 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 17, 2018</study_first_posted>
  <last_update_submitted>April 17, 2018</last_update_submitted>
  <last_update_submitted_qc>April 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

